These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9220041)

  • 1. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Ann Pharmacother; 1997; 31(7-8):842-6. PubMed ID: 9220041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP; Lim HL; Kueh YK
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
    Hull RD; Pineo GF; Raskob GE
    Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy.
    Lloyd A; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Pharmacoeconomics; 1997 Oct; 12(4):475-85. PubMed ID: 10174313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute deep vein thrombosis in spinal cord injured patients with enoxaparin: a cost analysis.
    Tomaio A; Kirshblum SC; O'Connor KC; Johnston M
    J Spinal Cord Med; 1998 Jul; 21(3):205-10. PubMed ID: 9863930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low molecular weight heparins. No increase of the cost of treatment of deep venous thrombosis].
    Levesque H; Cailleux N; Courtois H
    Presse Med; 1994 Apr 30-May 7; 23(17):816. PubMed ID: 8078843
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
    van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
    Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
    Osterkorn D; Schramm W; Szucs T
    Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
    Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
    Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis.
    Barber ND; Hoffmeyer UK
    Ann R Coll Surg Engl; 1993 Nov; 75(6):430-3. PubMed ID: 8285546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study.
    Belcaro G; Nicolaides AN; Errichi BM; Cesarone MR; De Sanctis MT; Incandela L; Venniker R
    Angiology; 1999 Jul; 50(7):523-9. PubMed ID: 10431991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients.
    Hull RD; Feldstein W; Pineo GF; Raskob GE
    Thromb Haemost; 1995 Jul; 74(1):189-96. PubMed ID: 8578456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.